{"schema_version":"secwatch.filing_event.v1","accession":"0001295947-26-000006","form_type":"8-K","ticker":"PBH","cik":"0001295947","company_name":"Prestige Consumer Healthcare Inc.","filed_at":"2026-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.736049+00:00","generated_at":"2026-05-16T04:19:08.876672+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prestige Q3 revenue $283.4M, down 2.4% YoY; adjusted EPS $1.14 vs $1.22","bullets":["GAAP diluted EPS $0.97; adjusted diluted EPS $1.14 (down from $1.22); net income $46.7M.","Narrowed FY2026 revenue outlook to ~$1.1B from $1.1-1.115B; adjusted EPS ~$4.54.","Repurchased ~0.8M shares in Q3 for $45.8M; YTD repurchases ~2.3M shares at $155.6M.","Closed acquisition of eye care supplier Pillar5 Pharma in December 2025.","Clear Eyes supply constraints continue; management expects supply improvements in coming quarters."],"urls":{"canonical":"https://secwatch.observer/filing/0001295947-26-000006","json":"https://secwatch.observer/filing/0001295947-26-000006.json","markdown":"https://secwatch.observer/filing/0001295947-26-000006.md","text":"https://secwatch.observer/filing/0001295947-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1295947/000129594726000006/0001295947-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1295947/000129594726000006/pbh-20260205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:19:08.876672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}